299 related articles for article (PubMed ID: 34547511)
21. [Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
Yukitake M
Brain Nerve; 2022 Oct; 74(10):1179-1187. PubMed ID: 36198643
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Major EO; Yousry TA; Clifford DB
Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
[TBL] [Abstract][Full Text] [Related]
23. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
24. Treatment of natalizumab-associated PML with filgrastim.
Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
[TBL] [Abstract][Full Text] [Related]
25. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
Moser T; Zimmermann G; Baumgartner A; Berger T; Bsteh G; Di Pauli F; Enzinger C; Fertl E; Heller T; Koppi S; Rommer PS; Safoschnik G; Seifert-Held T; Stepansky R; Sellner J
J Neurol; 2024 Jan; 271(1):374-385. PubMed ID: 37728757
[TBL] [Abstract][Full Text] [Related]
27. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
[TBL] [Abstract][Full Text] [Related]
28. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
29. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
30. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
32. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
33. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
34. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.
Borie D; Kremer JM
Semin Arthritis Rheum; 2015 Oct; 45(2):163-6. PubMed ID: 26190565
[TBL] [Abstract][Full Text] [Related]
35. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV; Zaçe D; Braccialarghe N; Massa B; Barchi V; Iannazzo R; Fato I; De Maria F; Kontogiannis D; Malagnino V; Sarmati L; Iannetta M
Drug Saf; 2024 Apr; 47(4):333-354. PubMed ID: 38321317
[TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
37. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
38. PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
[TBL] [Abstract][Full Text] [Related]
39. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
40. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]